Related Experiment Videos
Prevalent mutations in fatty acid oxidation disorders: diagnostic considerations
N Gregersen1, B S Andresen, P Bross
1Research Unit for Molecular Medicine, Aarhus University Hospital, Denmark. nig@mmf.au.dk
European Journal of Pediatrics
|February 24, 2001
Summary
Prevalent mutations in fatty acid oxidation genes show varying disease risks. Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency poses life-threatening risks, while short-chain acyl-CoA dehydrogenase (SCAD) variations require additional factors for disease manifestation.
Area of Science:
- Biochemistry
- Genetics
- Molecular Biology
Background:
- The mutational spectrum of disease-associated genes often includes a few highly prevalent mutations.
- Four genes involved in fatty acid oxidation (MCAD, SCAD, LCHAD, CPT II) are known to harbor prevalent mutations.
Purpose of the Study:
- To investigate the clinical significance and penetrance of prevalent mutations in genes regulating fatty acid oxidation.
- To understand the relationship between genotype and phenotype in disorders of fatty acid oxidation.
Main Methods:
- Analysis of mutation prevalence in disease-associated genes.
- Correlation of specific mutations with disease risk and manifestation.
- Review of existing data and identification of areas requiring further research.
Main Results:
- Individuals with the prevalent 985A > G mutation in the MCAD gene face a significant risk of life-threatening attacks.
- Prevalent variations in the SCAD gene (625A and 511T) appear to necessitate additional genetic or cellular factors for disease phenotype expression.
- Further data are required to determine the penetrance and disease risk associated with prevalent mutations in the LCHAD and CPT II genes.
Conclusions:
- Assessing prevalent mutation frequency and carrier rates can elucidate genotype penetrance in genetic disorders.
- This approach is particularly relevant for understanding disorders of mitochondrial fatty acid oxidation.